Veranex, a technology service provider focused on the medical technology industry, has purchased Devicia, a clinical consulting firm, Clarvin, a provider of strategic guidance in regulatory affairs and quality assurance.

The two companies were part of a transaction in which Veranex acquired a portfolio of full-service medical device consultancy companies. The acquisitions of affiliate companies Kickfile, Lea Reg and Limulus Bio were also part of the deal. The transaction expands Veranex’s European footprint and builds regulatory, clinical and quality service segments.

“This group of companies, led by Devicia and Clarvin, shares the same goal as Veranex: working with our clients to achieve and accelerate MedTech innovation,” comments Veranex CEO David Dockhorn. “Devicia, Clarvin, and their affiliate companies all focus exclusively on medical devices and IVD, providing strategic guidance and informed execution across a number of areas, including clinical trial, medical writing, regulatory strategies, toxicology assessments, designated local representation, and system technologies that bolster Veranex’s full-service med-tech capabilities and solutions.”

Alvarez & Marsal served as financial advisor and McDermott Will & Emery served as legal advisor to Veranex on this transaction. Christopher Fägerskiöld AB served as financial advisor and Kanter as legal advisor to Devicia and Clarvin group.